Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Amylin (Islet Amyloid Polypeptide).

One hour after initiation of infusion, patients consumed a Sustacal test meal.

The protocol was repeated on the following day with each patient receiving the alternate study medication.

Who Took Part

According to the abstract, 24 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

Only one side, usually the patients, was kept unaware of whether Amylin (Islet Amyloid Polypeptide) was given.

A placebo (an inactive look-alike) gave the Amylin (Islet Amyloid Polypeptide) group a baseline to be compared against.

In the crossover set-up each of the patients took both Amylin (Islet Amyloid Polypeptide) and the comparison in turn, acting as their own control.

What Was Measured

One hour after initiation of infusion, patients consumed a Sustacal test meal.

Topics PubMed links to this paper include Amyloid, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Gastrointestinal Diseases, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.